Triclabendazole
- Generic Name
- Triclabendazole
- Brand Names
- Egaten
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9Cl3N2OS
- CAS Number
- 68786-66-3
- Unique Ingredient Identifier
- 4784C8E03O
- Background
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. Fascioliasis is a parasitic infection often caused by the helminth, Fasciola hepatica, which is also known as “the common liver fluke” or “the sheep liver fluke” or by Fasciola giganti...
- Indication
This drug is indicated for the treatment of fascioliasis in patients aged 6 years old and above.
- Associated Conditions
- Fascioliasis
- Associated Therapies
- -
One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Universidad Peruana Cayetano Heredia
- Target Recruit Count
- 336
- Registration Number
- NCT06367361
Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)
- Conditions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT01931085
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath